Pre-clinical stage company developing bispecific antibodies against a novel subset of immunosuppressive cells to treat resistant cancers.
Biograph 55
Oncology
Total Addressable Market
Red Tree Board Member(s)
Red Tree Board Member
Jennifer Cochran, Ph.D.
Red Tree Board Observer
Samad Wahid, M.D.
Red Tree Participation
Led Series A
